Lumos Pharma Inc. Stock News

There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they are convinced they can gain from these kinds of investments after the market has reass

AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company is

Lumos Pharma's (LUMO) CEO Rick Hawkins on Q4 2020 Results - Earnings Call Transcript

AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results fo

AUSTIN, Texas, March 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, will present poster 7102 at th

Lumos (LUMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report

Lumos Pharma (LUMO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumo s Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company wi

AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company wil

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q3 2020 Results - Earnings Call Transcript

AUSTIN, Texas, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results f

AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will

AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report

FOR the five local trading sessions that spanned Sept 18 to 24, the Straits Times Index (STI) declined 2.0 per cent, with the Nikkei 225 Index, Hang Seng Index and S&P/ASX 200 Index averaging a 1.8 pe